Mild Traumatic Brain Injury & PTSD Study
Have you experienced a mild traumatic brain injury and suffer from PTSD?
You may be eligible to participate in this study.
Have you experienced a mild traumatic brain injury and suffer from PTSD? You may be eligible to participate in this study.
Frequently Asked Questions
What is iTBS?
iTBS is a type of transcranial magnetic stimulation. It is a non-invasive treatment that uses magnets on top of your head to change brain activity.
What will the attention training involve?
Attention training will be completed immediately after each iTBS session. A research assistant will set up a computer program where you will complete the training.
What tests are involved?
You will complete testing throughout your participation that includes filling out questionnaires about your symptoms and activities of daily living, tests of your thinking and memory skills, and will have an MRI completed three different times during your participation.
Can my doctor get the results of my tests?
Testing results will be reviewed with you at the end of your participation in the study and can be shared with your physician. MRI images are not available in a readable format to be given to you, but you would be notified if any concerning findings were noted.
How long are study sessions?
Sessions vary in length depending on what is being performed that day, but last approximately a half to full day. We will work to complete your schedule at the start of participation, so that you know when and for how long you would be needed each day.
Details for the study
Treatments and/or Procedures
Inclusion Criteria: - At least 18 years of age and no older than 60 years of age - 3 months to 10 years post exposure to mTBI event - Have co-occurring mTBI and PTSD as defined by the Symptom Attribution and Classification Algorithm (SACA) and the Clinically Administered PTSD Scale for DSM-V (CAPS-5) Exclusion Criteria: - Participating in another research study - Non-fluent in English (speaking and reading) - History of epilepsy pre-injury - Receiving antiepileptic treatment for documented active seizures in the past 6 months - Taking medications that lower seizure threshold including antipsychotics, buproprion, trazodone and tramadol - History of surgery on blood vessels in brain and/or valves of the heart - History of brain hemorrhage, neurovascular conditions and neurodegenerative disorders - History or current diagnosis of psychotic spectrum disorders (i.e. bipolar, schizophrenia) - Significant heart disease as determined by physician review of medical chart - Pregnant at time of enrollment or any time during study participation - MRI or TMS/iTBS contraindications such as claustrophobia, metal in eyes/face or brain - Cardiac pacemakers/defibrillators, cochlear implants, nerve stimulators, intracranial metal clips - Diagnosis of moderate or severe TBI (loss of consciousness > 30 minutes, alteration of consciousness > 24 hours, post traumatic amnesia or neuropsychological testing results - Mental health medications have been altered within the month preceding study screening - Taking prescribed CNS stimulants and choosing to not stop these medications during study participation - Testing positive for opiates and do not have a prescription for opiates. If on prescription opiates and taking more than the equivalent of 200 mg of morphine per day. - Taking tricyclic antidepressants - Questionably valid test performance as indicated by a score of ≤ 85% on the Immediate Recognition, Delayed Recognition or Consistency Scales of the Medical Symptom Validity Test (MSVT) and clinical determination of questionable performance validity by a neuropsychologist on the research team - Actively suicidal as evidenced by plan to harm or recent attempt communicated on the Structured Clinical Interview for DSM-V (SCID-5). - Increased Intracranial Pressure (ICP) as evidenced through a funduscopic evaluation or on the baseline MRI scan. - Moderate or severe cannabis use disorder defined by ≥ 4 symptoms on the SCID-5 - Severe alcohol use disorder defined by ≥ 4 symptoms on the SCID-5